IMR Press / FBL / Volume 20 / Issue 7 / DOI: 10.2741/4361

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

MicroRNAs in colorectal cancer: potential biomarkers and therapeutic targets
Show Less
1 Interventional Department, Tongren Hospital affiliated to Shanghai Jiaotong University School of Medicine, No.786, Yuyuan Road, Shanghai 200050, China
Front. Biosci. (Landmark Ed) 2015, 20(7), 1092–1103;
Published: 1 June 2015
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)

Colorectal Cancer (CRC) is one of the most common malignant tumors of gastrointestinal tract. The occurrence, development, diagnosis and prognosis have become a hot topic in current clinical research. However, current diagnosis and treatment still depend on the results of tumor imaging or pathology test. Therefore, to reveal the biological pathogenesis of CRC and to discover specific biomarkers for early diagnosis and better prognosis assessment of CRC have become key roles in current studies. Recent literature has revealed that aberrant expression of microRNAs (miRNAs) could contribute to the development and progression of CRC through the regulation of several critical pathways, including apoptosis, epithelial-mesenchymal transition, angiogenesis and signal transduction. These findings have also indicated that miRNAs could be a novel biomarker for early clinical diagnosis and prognosis evaluation of CRC. In this review, we have summarized the recent studies of miRNAs on the diagnosis, treatment and prognosis clinical biomarker of CRC. We also discussed the regulatory mechanisms of miRNAs in CRC, which may guide the future treatment for CRC.

Colorectal Cancer
Back to top